Xoma

XOMA Corporation is a biotechnology company focused on the discovery and development of therapeutic candidates across the United States, Europe, and the Asia Pacific. The company specializes in monoclonal antibodies and has a proprietary pipeline that includes several innovative product candidates, such as X213, an allosteric inhibitor of prolactin action, and XMetA, an insulin receptor-activating antibody designed to manage Type 2 diabetes. Additionally, XOMA is involved in developing therapies for metastatic melanoma and renal cell carcinoma, and it is advancing a pipeline targeting primary hyperparathyroidism. Beyond its proprietary candidates, XOMA licenses technologies related to antibody discovery and development. The company collaborates with notable pharmaceutical firms, fostering research and development partnerships. Founded in 1981 and based in Emeryville, California, XOMA plays a significant role in improving health outcomes through its innovative therapeutic approaches and strategic collaborations.